Immunome Inc. — Director's Dealing 2020

Oct 9, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immunome Inc. (IMNM)
CIK: 0001472012
Period of Report: 2020-10-06

Reporting Person: RAPP MICHAEL (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-10-06	Common Stock	C	555554	—	Acquired	555554	Direct
2020-10-06	Common Stock	P	83332	$12.00	Acquired	638886	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-10-06	Series A Convertible Preferred Stock	$	C	555554	Disposed		Common Stock (555554)	Direct
2020-10-06	Warrant (right to buy)	$9.00	C	166666	Disposed	2023-06-02	Series A Convertible Preferred Stock (166666)	Direct
2020-10-06	Warrant (right to buy)	$9.00	C	166666	Acquired	2023-06-02	Common Stock (166666)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	827640	Indirect

Footnotes

F1: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the
Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.

F2: The shares are held by BCM Advisory Partners LLC (the "LLC"). The Reporting Person is a managing member of the LLC and has voting and investment power with respect to shares held by the LLC.

F3: Each share of Series A Convertible Preferred Stock underlying this warrant automatically converted into shares of Common Stock upon the
closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.

F4: Immediately exercisable.